SciELO - Scientific Electronic Library Online

vol.33 issue6Serial heart rate changes in rats inoculated by conjunctival instillation of Trypanosoma cruzi obtained from bug faecesBancroftian filariasis in urban areas of Alagoas State, Northeast Brazil: study in general population author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista da Sociedade Brasileira de Medicina Tropical

Print version ISSN 0037-8682On-line version ISSN 1678-9849


DEPS, Patrícia D.; VIANA, Maria Carmen; FALQUETO, Aloísio  and  DIETZE, Reynaldo. Evaluation of the efficacy and toxicity of N-methyl-glucamine vs BP88® Sodium Stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. [online]. 2000, vol.33, n.6, pp.535-543. ISSN 0037-8682.

This randomized, single blind clinical trial was performed to compare the efficacy and toxicity of BP88 Sodium Stibogluconate (SS) to Glucantime® (N-methyl-glucamine), (GL). Sixty-three patients were randomly assigned to one of two groups: 32 patients were treated with GL and 3l patients were treated with SS. Both groups received 15mg Sb+5/kg/day for 20 days. Toxicity was evaluated through EKG, urea, creatinine, AST, ALT, alkaline phosphatase, amylase, and lipase, assessed before treatment, on day 10 and day 20 of treatment and 90 days after treatment. In the group treated with GL, 81% (26/32) of patients were cured compared to 77% (24/31) in the SS group. Five (16%) patients relapsed in the GL group compared to 6 (19%) in the SS group. One patient in each group did not respond to treatment. AST, ALT, amylase, and lipase were more elevated in the SS group (p < 0.05). In conclusion, the efficacy of both treatments was similar although there was more toxicity in the ES group.

Keywords : Cutaneous leishmaniasis; Glucantime®; BP88® sodium stibogluconate; Treatment; Efficacy; Randomized clinical trial.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License